1 / 6

Alpha PRRT Advancing the Treatment of Neuroendocrine Tumors

Alpha PRRT (Peptide Receptor Radionuclide Therapy) is a groundbreaking treatment for neuroendocrine tumors (NETs) that uses targeted alpha-emitting isotopes. Unlike traditional beta-emitting therapies, alpha particles deliver more potent radiation to tumors, resulting in improved efficacy, especially for small or resistant tumors. This therapy provides a targeted, effective treatment option for patients with advanced NETs, offering significant tumor shrinkage and improved survival rates. The precision of Alpha PRRT reduces the impact on surrounding healthy tissues, making it a promising option

Nuclearmedicinetherapy
Download Presentation

Alpha PRRT Advancing the Treatment of Neuroendocrine Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear Medicine Centre FMRi Gurugram INDIA Dr. Ishita B Sen Alpha PRRT: Advancing the Treatment of Neuroendocrine Tumors www.nuclearmedicinetherapy.in

  2. Understanding Alpha PRRT • Definition: Alpha Peptide Receptor Radionuclide Therapy (PRRT) uses alpha-emitting isotopes like Actinium-225 (^225Ac) to target neuroendocrine tumors (NETs). • Mechanism: Delivers high-energy, short-range alpha particles directly to tumor cells, causing irreparable DNA damage. • Advantage: Minimizes harm to surrounding healthy tissues due to the short path length of alpha particles.​

  3. Advantages Over Beta PRRT (Lu-177) • Higher Tumor Cell Killing Efficiency: Alpha particles deliver 100–1000 times more energy per unit track length compared to beta particles, ensuring effective eradication of tumor cells. • Overcoming Resistance: Effective in patients who have developed resistance to Lu-177 therapy. • Reduced Side Effects: Lower radiation exposure to healthy tissues leads to fewer side effects like fatigue and renal complications.

  4. Clinical Applications and Efficacy • Patient Selection: Ideal for patients with advanced-stage or refractory NETs. • Treatment Protocol: Fewer treatment cycles required due to high potency, leading to shorter overall treatment duration. • Outcomes: Improved disease stabilization and progression-free survival rates.​

  5. Conclusion • Alpha PRRT with Actinium-225 represents a significant advancement in the treatment of NETs, offering higher efficacy and a better safety profile compared to traditional beta-emitting therapies. • Future Outlook: Continued research and clinical trials are expected to further establish its role in standard care protocols for NETs.​

  6. For more information talk to Dr. Ishita B Sen today. dr.ishitasen@nuclearmedicinetherapy.in +91 8700 668 431 www.nuclearmedicinetherapy.in

More Related